Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

444

Enrollment

INDUSTRY

Sponsor class

Conditions

Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
Endometrial Cancer
Head and Neck Cancer
Hepatocellular Carcinoma (HCC)
Gastric Cancer
Lung Cancer
Lymphoma
Renal Cell Carcinoma (RCC)
Ovarian Cancer
Solid Tumors
UC (Urothelial Cancer)
Melanoma
Bladder Cancer
Triple Negative Breast Cancer (TNBC)

Interventions

DRUG: MK-3475
DRUG: INCB024360

Sponsor

Incyte Corporation

Collaborators

[object Object]